Evidence map›Paper›PMID 38540420›Full record

ArticleGenes2024

Genomic Characterization of SARS-CoV-2 Variants from Clinical Isolates during the COVID-19 Epidemic in Mauritania.

Jemila Deida, Nasserdine Papa Mze, Mamadou Beye, Sidi Mohamed Ahmed, Ahmed El Bara, Mohamed Abdallahi Bollahi, Leonardo Basco, Ali Ould Mohamed Salem Boukhary, Pierre-Edouard Fournier

Open access · goldAbstract read
In one paragraph

Article in Genes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Jemila DeidaUR-Génomes et Milieux, Université de Nouakchott, Nouakchott BP 880, Mauritania.
Nasserdine Papa MzeAix Marseille University, AP-HM, SSA, VITROME, 13005 Marseille, France.ORCID 0000-0002-1415-4882
Mamadou BeyeAix Marseille University, AP-HM, SSA, VITROME, 13005 Marseille, France.
Sidi Mohamed AhmedInstitut National de Recherche en Santé Publique, Nouakchott BP 695, Mauritania.
Ahmed El BaraInstitut National de Recherche en Santé Publique, Nouakchott BP 695, Mauritania.
Mohamed Abdallahi BollahiInstitut National de Recherche en Santé Publique, Nouakchott BP 695, Mauritania.
Leonardo BascoAix Marseille University, AP-HM, SSA, VITROME, 13005 Marseille, France.ORCID 0000-0002-8812-8185
Ali Ould Mohamed Salem BoukharyUR-Génomes et Milieux, Université de Nouakchott, Nouakchott BP 880, Mauritania.ORCID 0000-0001-7317-2776
Pierre-Edouard FournierAix Marseille University, AP-HM, SSA, VITROME, 13005 Marseille, France.
Aix-Marseille Université · FRUniversité de Nouakchott · MR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rapid genetic evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during the coronavirus disease 2019 (COVID-19) pandemic has greatly challenged public health authorities worldwide, including in Mauritania. Despite the presence of the virus in Mauritania, only one study described its genomic variation during the course of the epidemic. The purpose of the present study was to document the genomic pattern of SARS-CoV-2 variants from clinical isolates during the COVID-19 outbreak in Mauritania, from September to November 2021. The whole genomes from 54 SARS-CoV-2 strains detected in nasopharyngeal swabs with a cycle threshold value ≤ 30 were successfully sequenced using next-generation sequencing (NGS) and the Illumina protocol. The mean genome coverage (±standard deviation) was 96.8% (±3.7). The most commonly identified clade was 21J (57.4%), followed by 21D (16.7%), 20A (11.1%), and 20B (9.2%). At the level of lineages, the majority of the samples were Delta variants with the sub-lineage AY.34 (or B.1.617.2.34). Among the 54 SARS-CoV-2 isolates that were successfully sequenced, 33 (61.1%) came from vaccinated individuals, and 21 (38.9%) were from unvaccinated individuals. Several SARS-CoV-2 variants were present in Mauritania between September and November 2021. As Mauritania, like many West African countries, is resource-limited regarding viral genome sequencing facilities, establishment of mutualized sub-regional sequencing platforms will be necessary to ensure continuous monitoring of mutations in viral genomes and track potential reduction in COVID-19 vaccine efficacy, increased transmissibility, and disease severity.

Indexed as

COVID-19SARS-CoV-2COVID-19 VaccinesGenomicsHumansMauritaniaPandemicsCOVID-19 VaccinescoronavirusCOVID-19MauritaniaSARS-CoV-2variants

Identifiers

PMID38540420
PMCPMC10970642
OpenAlexW4392810347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.